Ubs Group Ag Clearside Biomedical, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Clearside Biomedical, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 62,069 shares of CLSD stock, worth $52,137. This represents 0.0% of its overall portfolio holdings.

Number of Shares

62,069

Previous 145,118 57.23%

Holding current value

$52,137

Previous $145,000 60.69%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	SELL	$0.79 - $1.13 $65,608 - $93,845	-83,049 Reduced 57.23%	62,069 $57,000
Q4 2024 Feb 14, 2025	BUY	$0.87 - $1.58 $126,252 - $229,286	145,118 New	145,118 $145,000
Q1 2024 May 13, 2024	BUY	$1.2 - $2.02 $9,213 - $15,509	7,678 New	7,678 $11,000
Q2 2023 Aug 11, 2023	SELL	$0.97 - $1.48 $3,539 - $5,400	-3,649 Reduced 59.26%	2,509 $2,000
Q1 2023 May 12, 2023	BUY	$0.93 - $1.66 $5,726 - $10,222	6,158 New	6,158 $6,000
Q3 2022 Nov 10, 2022	BUY	$1.08 - $1.83 $4,491 - $7,610	4,159 Added 945.23%	4,599 $5,000
Q2 2022 Aug 10, 2022	SELL	$1.3 - $2.49 $3,905 - $7,479	-3,004 Reduced 87.22%	440 $0
Q1 2022 May 16, 2022	SELL	$1.35 - $2.88 $9,035 - $19,275	-6,693 Reduced 66.03%	3,444 $8,000
Q4 2021 Feb 14, 2022	BUY	$2.72 - $5.72 $9,136 - $19,213	3,359 Added 49.56%	10,137 $28,000
Q3 2021 Nov 15, 2021	BUY	$4.83 - $7.2 $1,023 - $1,526	212 Added 3.23%	6,778 $41,000
Q2 2021 Aug 13, 2021	BUY	$2.32 - $5.38 $1,313 - $3,045	566 Added 9.43%	6,566 $32,000
Q1 2021 May 12, 2021	SELL	$2.24 - $4.25 $6,876 - $13,047	-3,070 Reduced 33.85%	6,000 $15,000
Q4 2020 Feb 11, 2021	SELL	$1.32 - $2.74 $13,140 - $27,276	-9,955 Reduced 52.33%	9,070 $24,000
Q3 2020 Nov 12, 2020	BUY	$1.45 - $2.0 $4,120 - $5,684	2,842 Added 17.56%	19,025 $29,000
Q2 2020 Jul 31, 2020	SELL	$1.55 - $2.41 $3,292 - $5,118	-2,124 Reduced 11.6%	16,183 $30,000
Q1 2020 May 01, 2020	SELL	$1.32 - $3.77 $8,371 - $23,909	-6,342 Reduced 25.73%	18,307 $31,000
Q4 2019 Feb 14, 2020	SELL	$0.62 - $3.4 $10,992 - $60,282	-17,730 Reduced 41.84%	24,649 $71,000
Q3 2019 Nov 14, 2019	BUY	$0.59 - $1.32 $24,969 - $55,863	42,321 Added 72967.24%	42,379 $27,000
Q2 2019 Aug 14, 2019	SELL	$0.97 - $1.42 $4,384 - $6,418	-4,520 Reduced 98.73%	58 $0
Q1 2019 May 14, 2019	SELL	$1.1 - $1.74 $998,435 - $1.58 Million	-907,669 Reduced 99.5%	4,578 $6,000
Q4 2018 Feb 14, 2019	BUY	$1.0 - $6.12 $909,706 - $5.57 Million	909,706 Added 35801.1%	912,247 $976,000
Q3 2018 Nov 14, 2018	SELL	$6.03 - $11.24 $22,353 - $41,666	-3,707 Reduced 59.33%	2,541 $16,000
Q2 2018 Aug 14, 2018	BUY	$8.91 - $14.54 $37,297 - $60,864	4,186 Added 203.01%	6,248 $67,000
Q1 2018 May 15, 2018	SELL	$5.57 - $14.28 $8,494 - $21,777	-1,525 Reduced 42.51%	2,062 $22,000
Q4 2017 Feb 14, 2018	SELL	$5.78 - $9.12 $5,543 - $8,746	-959 Reduced 21.1%	3,587 $25,000
Q3 2017 Nov 14, 2017	BUY	$6.73 - $8.74 $11,743 - $15,251	1,745 Added 62.3%	4,546 $40,000
Q2 2017 Aug 14, 2017	SELL	N/A	-2,225 Reduced 44.27%	2,801 $26,000
Q1 2017 Nov 14, 2017	BUY	N/A	5,026	5,026 $40,000

Others Institutions Holding CLSD

# of Institutions

Shares Held

11M

Call Options Held

5.9K

Put Options Held

86.6K

View Full List

About Clearside Biomedical, Inc.

Ticker CLSD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,190,700
Market Cap $50.6M
Description
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injec...

More about CLSD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account